Company News for November 2, 2022

  • Shares of Abiomed, Inc. ABMD jumped 49.9% after the company reported earnings of $1.30 per share in the third quarter of 2022, beating Zacks’ consensus estimate of $1.05 per share. stock.
  • ArcBest Corporation’s ARCB shares gained 1% after the company reported Q3 2022 earnings of $3.80 per share, beating Zacks’ consensus estimate of $3.75 per share.
  • Shares of Marathon Petroleum Corporation MPC jumped 4.9% after the company reported third-quarter 2022 earnings of $7.81 per share, beating Zacks’ consensus estimate of $6.80 per share.
  • TAP shares of Molson Coors Beverage Company fell 3.2% after the company reported third-quarter 2022 earnings of $1.32 per share, missing Zacks consensus estimate of $1.36 per share .

Zacks names ‘only one best choice for doubling up’

From thousands of stocks, 5 Zacks experts have each picked their favorite to skyrocket by +100% or more in the coming months. Of these 5, Research Director Sheraz Mian selects one to have the most explosive advantage of all.

It’s a little-known chemical company that’s up 65% year-on-year, but still very cheap. With relentless demand, rising earnings estimates for 2022 and $1.5 billion for stock buybacks, retail investors could step in at any time.

This company could rival or surpass other recent Zacks stocks which are expected to double like Boston Beer Company which jumped +143.0% in just over 9 months and NVIDIA which jumped +175.9% in one year .

Free: See our best stock and our 4 finalists >>

Want the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click to get this free report

ABIOMED, ​​Inc. (ABMD): Free Stock Analysis Report

Molson Coors Beverage Company (TAP): Free Inventory Analysis Report

Marathon Petroleum Corporation (MPC): Free Stock Analysis Report

ArcBest Corporation (ARCB): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Karen J. Nelson